ARTBIO, currently in stealth mode, is developing radioligand therapies for the treatment of cancers—with prostate, solid tumors, osteosarcoma, pancreatic, and non-small cell lung cancer being its initial focus.
In early 2022, Occam recruited Emanuele Otsuni, PhD as the company’s first CEO. Prior to assuming the CEO role at ARTBIO, Emanuele served as Head of European Cell & Gene Therapy programs at Novartis.
About Occam Global
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.